financetom
Business
financetom
/
Business
/
Poet Technologies Shares Rise After Announcing $25 Million Public Offering
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Poet Technologies Shares Rise After Announcing $25 Million Public Offering
May 25, 2025 8:11 PM

11:31 AM EDT, 04/28/2025 (MT Newswires) -- Poet Technologies ( POET ) shares were up 4.2% in recent Monday trading after the company said it plans to sell 5 million units at $5 apiece in a public offering for gross proceeds of $25 million.

Each unit comprises one common share and one common share purchase warrant, with each warrant allowing the holder to buy one common share for 8.32 Canadian dollars ($6.01), exercisable over five years, the company said.

Net proceeds will be used for working capital and general corporate needs, the company said.

A single Canadian institutional investor is expected to fully subscribe to the offering, the company added.

Price: 4.28, Change: +0.17, Percent Change: +4.23

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Oct 17, 2025
Company announcement – No. 22 / 2025 Zealand Pharma ( ZLDPF ) major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, October 17, 2025 – Zealand Pharma A/S ( ZLDPF ) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 16 October 2025 of notification pursuant to Section 38...
Bristol-Myers Squibb, SystImmune Report 'Promising' Results for Cancer Drug in Phase 1 Study
Bristol-Myers Squibb, SystImmune Report 'Promising' Results for Cancer Drug in Phase 1 Study
Oct 17, 2025
11:10 AM EDT, 10/17/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) and SystImmune said Friday that a phase 1 study of the antibody-drug conjugate iza-bren showed promising anti-tumor activity and manageable safety profile. Presenting data at the European Society for Medical Oncology Congress in Berlin, the companies said the trial showed a 55% confirmed response rate among patients receiving...
UN shipping agency delays decision on carbon price for one year amid splits
UN shipping agency delays decision on carbon price for one year amid splits
Oct 17, 2025
LONDON -A majority of countries at the U.N. shipping agency voted on Friday to postpone by a year a decision on a global carbon price on international shipping, after failing to reach consensus on the emissions reduction measure amid U.S. pressure. The decision to delay the deal is a blow to the European Union and other countries including Brazil which...
Canaccord Genuity Group Jumps Near 20%, Comments on Reports of Possible Sale of British Business
Canaccord Genuity Group Jumps Near 20%, Comments on Reports of Possible Sale of British Business
Oct 17, 2025
11:09 AM EDT, 10/17/2025 (MT Newswires) -- Canaccord Genuity Group ( CCORF ) , up near 20% to a multi-year high, Friday commented on a news article speculating about a potential sale of Canaccord's UK wealth management business. The company said in a statement that it routinely evaluates strategic initiatives which sometimes involve discussions with potential counterparties, however, there can...
Copyright 2023-2026 - www.financetom.com All Rights Reserved